Andrew Obenshain Sells 21,805 Shares of bluebird bio, Inc. (NASDAQ:BLUE) Stock
Andrew Obenshain Sells 21,805 Shares of bluebird bio, Inc. (NASDAQ:BLUE) Stock
bluebird bio, Inc. (NASDAQ:BLUE – Get Rating) CEO Andrew Obenshain sold 21,805 shares of the company's stock in a transaction dated Thursday, August 4th. The stock was sold at an average price of $4.39, for a total transaction of $95,723.95. Following the completion of the transaction, the chief executive officer now owns 247,131 shares in the company, valued at approximately $1,084,905.09. The sale was disclosed in a legal filing with the SEC, which is available through this link.
藍鳥生物公司(Bluebird Bio,Inc.)首席執行官安德魯·奧本斯坦在日期為8月4日(星期四)的交易中出售了21,805股該公司股票。該股以4.39美元的平均價格出售,總成交金額為95723.95美元。交易完成後,首席執行官現在擁有該公司247,131股,價值約1,084,905.09美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的,可以通過這個鏈接獲得。
bluebird bio Stock Up 13.4 %
藍鳥生物股票上漲13.4%
BLUE traded up $0.75 during trading on Monday, hitting $6.34. The company's stock had a trading volume of 10,617,046 shares, compared to its average volume of 4,637,974. The business's 50 day simple moving average is $4.22 and its 200-day simple moving average is $4.76. The firm has a market cap of $453.02 million, a PE ratio of -0.74 and a beta of 1.29. bluebird bio, Inc. has a one year low of $2.87 and a one year high of $25.39.
在週一的交易中,Blue的交易價格上漲了0.75美元,達到6.34美元。該公司股票的成交量為10,617,046股,而其平均成交量為4,637,974股。該業務的50日簡單移動均線切入位為4.22美元,200日簡單移動均線切入位為4.76美元。該公司市值為4.5302億美元,市盈率為-0.74,貝塔係數為1.29。藍鳥生物公司的一年低點為2.87美元,一年高位為25.39美元。
bluebird bio (NASDAQ:BLUE – Get Rating) last announced its earnings results on Monday, May 9th. The biotechnology company reported ($1.66) EPS for the quarter, missing analysts' consensus estimates of ($1.26) by ($0.40). bluebird bio had a negative return on equity of 130.19% and a negative net margin of 2,141.34%. The company had revenue of $1.95 million during the quarter, compared to the consensus estimate of $0.17 million. During the same period in the prior year, the business posted ($3.07) earnings per share. bluebird bio's revenue for the quarter was up 117.6% compared to the same quarter last year. Equities research analysts expect that bluebird bio, Inc. will post -5.07 EPS for the current fiscal year.
青鳥生物(納斯達克:Blue-Get Rating)最近一次公佈財報是在5月9日(星期一)。這家生物技術公司公佈的季度每股收益為1.66美元,低於分析師普遍預期的1.26美元和0.40美元。藍鳥生物的淨資產回報率為負130.19%,淨利潤率為負2,141.34%。該公司本季度營收為195萬美元,而市場普遍預期為17萬美元。去年同期,該業務公佈的每股收益為3.07美元。藍鳥生物本季度的收入與去年同期相比增長了117.6。股票研究分析師預計,藍鳥生物公司本財年每股收益將達到5.07歐元。
Hedge Funds Weigh In On bluebird bio
對衝基金對藍鳥生物的看法
Analyst Ratings Changes
分析師評級發生變化
Several research analysts have recently issued reports on the stock. Raymond James upgraded shares of bluebird bio from a "market perform" rating to an "outperform" rating and set a $8.00 target price on the stock in a research note on Tuesday, August 2nd. Wedbush cut their target price on bluebird bio from $10.00 to $8.00 and set a "neutral" rating on the stock in a research note on Tuesday, May 10th. Morgan Stanley reduced their target price on bluebird bio to $3.00 and set an "underweight" rating for the company in a report on Tuesday, May 17th. Finally, Barclays raised bluebird bio from an "underweight" rating to an "equal weight" rating and increased their price objective for the company from $3.00 to $5.00 in a research report on Friday. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $11.86.
幾位研究分析師最近發佈了關於該股的報告。8月2日,雷蒙德·詹姆斯在一份研究報告中將藍鳥生物公司的股票評級從市場表現上調至跑贏大盤,併為該公司股票設定了8.00美元的目標價。5月10日,週二,韋德布什在一份研究報告中將藍鳥生物的目標價從10.00美元下調至8.00美元,並將該股的評級定為中性。摩根士丹利在5月17日週二的一份報告中將藍鳥生物的目標價下調至3.00美元,並將該公司的評級定為“減持”。最後,在上週五的一份研究報告中,巴克萊將藍鳥生物的評級從減持上調至同等權重,並將該公司的目標價從3.00美元上調至5.00美元。兩名分析師對該股的評級為賣出,12名分析師發佈了持有評級,兩名分析師發佈了買入評級,一名分析師對該公司股票給予了強烈的買入評級。根據MarketBeat.com的數據,該公司目前的普遍評級為持有,平均目標價為11.86美元。
About bluebird bio
關於藍鳥傳記
(Get Rating)
(獲取評級)
bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy.
藍鳥生物公司是一家生物技術公司,研究、開發和商業化針對嚴重遺傳病的變革性基因療法。其用於治療嚴重遺傳性疾病的候選產品包括用於治療輸血依賴型β-地中海貧血的貝替貝吉基因Autotemcel;用於治療鐮狀細胞病(SCD)的lovotieglogene autemcel;以及用於治療大腦腎上腺腦白質營養不良的伊利伐多烯Autotemcel。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on bluebird bio (BLUE)
- How to Use the MarketBeat Dividend Calculator
- Two Appealing Biotech Stocks for Two Distinct investors
- Is Tyson Foods A Buy On Post-Earnings Weakness?
- Is DoorDash Ready To Sprint Higher?
- Electric Vehicles Can Drive Alcoa Stock Higher
- 免費獲取StockNews.com關於藍鳥生物的研究報告(藍色)
- 如何使用MarketBeat分紅計算器
- 兩隻對兩個不同投資者有吸引力的生物技術股票
- 泰森食品是在盈利疲軟的基礎上買入的嗎?
- DoorDash準備好衝刺更高了嗎?
- 電動汽車可以推動美國鋁業股價走高
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.
獲得藍鳥生物日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對藍鳥生物和相關公司的最新新聞和分析師評級的每日簡明摘要。